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Abstract: Antibiotic resistance in bacteria is developing at a faster rate than new antibiotics can be 
discovered. This study investigated the antimicrobial activity of several carbon-based derivative 
compounds alone and in combination with clinically relevant antibiotics against key ESKAPE 
pathogens Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli. Three compounds, 
graphite, graphene and graphene oxide, in conjunction with ciprofloxacin (CIP), chloramphenicol 
(CHL) and piperacillin/tazobactam (TZP) were examined using fractional inhibitory concentration 
(FIC) testing. CIP combined with graphene demonstrated additive antimicrobial activity against E. 
faecium compared to individual application. Furthermore, CIP supplemented with graphene, 
graphene oxide or graphite showed additive activity with ∑FIC values of 1.0 against K. pneumoniae, 
whereas only TZP showed ∑FIC values <1.0 with graphene oxide. For E. coli, the antibiotic activity 
of CIP was enhanced with graphene, graphene oxide or graphite, whereas only graphite and graphene 
enhanced the activity of CHL and TZP respectively. Graphite and graphene oxide caused significant 
antagonism (∑FIC ˃ 4.0) in conjunction with TZP against E. coli. In conclusion, the results 
demonstrate the potential to supplement clinically relevant antibiotics with carbon-based graphene, 
graphene oxide derivative or graphite for use as an additive supplement for novel systemic or topical 
treatment solutions against key priority pathogens. 
Keywords: graphene; ESKAPE pathogens; synergy; antibiotics; chloramphenicol; ciprofloxacin; 
piperacillin-tazobactam 
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1. Introduction 
Bacterial resistance to antibiotic treatments has become a significant global challenge [1], with 
more successful strategies being urgently required [2]. It has been suggested that combining 
graphene and derivatives with antibiotics might provide a novel approach to treating the most serious 
of resistant bacterial infections [3,4]. 
Graphene is a single layer of carbon atoms arranged into a honeycomb lattice [5]. The 
crystalline structure is held together by sp
2
 hybridisation of the carbon atoms [6]. Graphene is a 
two-dimensional structure which can be manipulated to form different carbon allotropes such as 
fullerenes (zero-dimensional) through wrapping, nanotubes by rolling (one-dimensional) or stacked 
into graphite (three-dimensional) [5,7]. Graphene oxide is produced by attaching functional groups to 
graphene sheets via oxidation. Epoxide and phenol hydroxyl groups attach to the basal plane whilst 
the edges of the graphene sheet are covered in carboxylic groups [8]. Graphene compounds have 
high surface energies that allow for strong absorption of ions and molecules which alter the bacterial 
microenvironment. Slight pH changes via hydroxyl and carboxyl dissociations change the 
environment and therefore bacterial proliferation is affected [9]. 
The in vitro antimicrobial properties of graphene and derivatives have been well established [4]. 
There are three main proposed mechanisms of antimicrobial activity of graphene and derivatives. 
Firstly, graphene-based compounds have nanoknives which physically disrupt the bacterial 
membrane via sharp edges causing leakage of intracellular substances; membrane integrity is lost 
and cell death occurs [8,9]. Secondly, oxidative stress via the generation of reactive oxygen species 
dependent/independent pathways may disrupt bacterial metabolism and cellular functions leading to 
cell death through apoptosis [9]. More specifically, inducible oxidative stress is the mode of action 
that is attributed to graphene [8]. Finally, a thin flexible barrier is created by the graphene lateral 
two-dimensional structure which wraps/traps the bacterial cell membrane preventing nutrient 
acquisition and disruption of optimum physiochemical growth condition [4]. This results in a 
decrease in cell viability and metabolic activity [9]. Indeed, the sheeted structure of graphene oxide 
can intertwine with the bacterial cell, reducing membrane accessibility [10]. These modes of action 
are very distinct from those of traditional antibiotics which have clearly defined target sites within 
the bacterial cell [11]. 
Despite the well-established antimicrobial properties of graphene and derivatives, so far these 
have been unsuitable for medical use due to low efficacy [4]. The high concentration of compound 
required to achieve sufficient in vivo antimicrobial activity is likely prohibitive when considering the 
requirements for clinical applications. To address this, some studies have conjugated graphene and 
derivatives with metals [12,13], natural products such as curcumin [14] and antibiotics [15] to study 
potential synergist effects. However, there is a dearth in knowledge regarding the choice of suitable 
antibiotic combinations, which promote synergy and avoid antagonism. 
In this study, three clinically relevant antibiotics with different modes of antimicrobial activity 
were selected. Ciprofloxacin (CIP), a fluoroquinolone, inhibits nucleic acid synthesis by inhibiting 
the activity of DNA Gyrase and Topoisomerase IV [16]. Chloramphenicol (CHL) inhibits     
protein synthesis by binding to the 50S ribosomal subunit which prevents the activity of peptidyl 
transferase [17]. Piperacillin is a β-lactam which inhibits the action of penicillin binding proteins 
which disrupts cell wall synthesis [18,19]. This is used in combination with tazobactam as 
piperacillin/tazobactam (TZP), a β-lactamase inhibitor which is designed to reduce resistance 
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generation [20]. Utilising the very distinct antibacterial properties of each antibiotic compared to 
those of graphene, graphene oxide and graphite, and using antimicrobial screening methods, we 
identified that combination therapy may provide a novel treatment option against well-characterised 
representative type strains of three ESKAPE pathogens, Enterococcus faecium, Klebsiella 
pneumoniae and Escherichia coli. 
2. Materials and methods 
2.1. Bacterial strains 
E. faecium strain NCTC 7171 was cultured using Columbia Blood agar (Oxoid, UK) 
supplemented with 5% horse blood (TCS Biosciences, UK) or Brain Heart Infusion (BHI) broth 
(Oxoid, UK) with agitation and incubated in anaerobic conditions at 37 °C for 24 h. K. pneumoniae 
strain NCTC 9633 and E. coli strain NCTC 10418 were cultured using Nutrient agar or broth (Oxoid, 
UK) and incubated in aerobic conditions at 37 °C for 24 h. 
2.2. Antimicrobial compounds 
Graphene, graphene oxide (aqueous solution) and graphite were supplied by Manchester 
Metropolitan University (UK) and prepared in distilled water. All antibiotics were obtained from 
Sigma-Aldrich (Poole, UK) with CIP solubilised in 0.1 M hydrochloric acid, CHL in 95% ethanol 
and TZP (manufacturer pre-prepared) in distilled water. 
2.3. Minimum inhibitory concentration (MIC) assay 
MIC values were determined for each antibiotic and graphene derivative by using a 96 well 
microbroth dilution assay [12]. Briefly, 0.15% (w/v) tetrazolium blue chloride (TBC) (Sigma-Aldrich, 
UK) was added to approximately 1.0 × 10
9
 colony forming units per mL of each bacterial inoculum 
(E. faecium, K. pneumoniae and E. coli) in 2× concentrated media. Aliquots of 100 μL culture were 
mixed with equal volumes of respective antimicrobial compounds and serially diluted sequentially to 
a final ten fold dilution. Ethanol (95%) and hydrochloric acid (0.1 M) solvent controls were included. 
Plates were incubated in aerobic or anaerobic conditions at 37 °C for 24 h. All experiments were 
conducted with n = 3. MIC values were recorded as the lowest concentration with no visible colour 
change. 
2.4. Fractional inhibitory concentration (FIC) assay 
FIC values were determined to identify synergistic antimicrobial activity between each 
antibiotic and carbon-based supplement against each bacterial species as described by Sopirala et al. 
(2010) [21]. Briefly, similar methods were employed as described above, however, 50 μL of each 
compound at twice concentration were added to the starting well before serial dilution prior to 
incubation and MIC determination. FIC for each antimicrobial compound was determined using the 
equation sum FIC = [(MICcompound with antibiotic/MICcompound alone) + (MICantibiotic with 
compound/MICantibiotic alone)], where compound relates to the carbon supplement and antibiotic 
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relates to CIP, CHL or TZP. The fractional index thresholds used were ≤ 0.5 indicating      
synergy, ˃ 0.5 ≤ 1 additivity, ˃ 1 ≤ 4 indifference and > 4 antagonism [21]. 
3. Results 
The fractional inhibitory concentration (FIC) was calculated to analyse synergistic relationships 
between each compound combined with selected antibiotics against all three bacterial strains. The 
fractional inhibitory concentration index analysis revealed additive, indifferent or antagonistic effects. 
Additive activity was observed when CIP was combined with graphene, graphene oxide or graphite 
against K. pneumoniae (Table 2) and E. coli (Table 3), but only graphene demonstrated additive 
effects (∑FIC = 0.56) against E. faecium (Table 1). 
All CHL combinations with graphene, graphene oxide and graphite resulted in indifferent 
activity against E. faecium, K. pneumoniae and E. coli within ∑FIC range 1.01–2.95 (Tables 1–3), 
with the exception of CHL which when supplemented with graphite demonstrated additive 
interactions against E. coli (∑FIC = 1.00) (Table 3) 
Table 1. FIC analysis of CIP, CHL and TZP in combination with graphene, graphene 
oxide and graphite against E. faecium. The fractional index points used were ≤ 0.5 
synergy, ˃ 0.5 ≤ 1 additivity, ˃ 1 ≤ 4 indifference and > 4 antagonism. (A) denotes 
carbon-based compound as shown, (B) represents antibiotics ciprofloxacin (CIP), 
chloramphenicol (CHL) and piperacillin/tazobactam (TZP). All MIC values are in mg/L. 
∑FIC, sum of the fractional inhibitory concentrations. Values are representative of three 
independent biological repeats. 
Compound 
(A) 
Antibiotic 
(B) 
MIC 
(A) 
MIC 
(A+B) 
MIC 
(B) 
MIC 
(B+A) 
∑FIC Inter Interaction 
Graphene CIP 500 31.3 0.62 0.31 0.56 Additive 
 CHL 500 7.81 0.16 0.47 2.95 Indifferent 
 TZP 500 250 2.22 42.5 19.6 Antagonistic 
Graphene 
oxide 
CIP 292 52.1 0.62 0.52 1.02 Indifferent 
CHL 292 5.21 0.16 0.31 1.96 Indifferent 
 TZP 292 52.1 2.22 8.85 4.17 Antagonistic 
Graphite CIP 250 62.5 0.62 0.63 1.27 Indifferent 
 CHL 250 3.91 0.16 0.23 1.45 Indifferent 
 TZP 250 15.6 2.22 2.65 1.26 Indifferent 
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Table 2. FIC analysis of CIP, CHL and TZP in combination with graphene, graphene 
oxide and graphite against K. pneumoniae. The fractional index points used were ≤ 0.5 
synergy, ˃ 0.5 ≤ 1 additivity, ˃ 1 ≤ 4 indifference and > 4 antagonism. (A) denotes 
carbon-based compound as shown, (B) represents antibiotics ciprofloxacin (CIP), 
chloramphenicol (CHL) and piperacillin/tazobactam (TZP). All MIC values are in mg/L. 
∑FIC, sum of the fractional inhibitory concentrations. Values are representative of three 
independent biological repeats. 
Compound 
(A) 
Antibiotic 
(B) 
MIC 
(A) 
MIC 
(A+B) 
MIC 
(B) 
MIC 
(B+A) 
∑FIC Interaction 
Graphene CIP 417 0.98 0.01 0.01 1.00 Additive 
 CHL 417 3.91 0.23 0.23 1.01 Indifferent 
 TZP 417 5.21 0.67 0.89 1.34 Indifferent 
Graphene 
oxide 
CIP 500 0.98 0.01 0.01 1.00 Additive 
CHL 500 5.21 0.23 0.31 1.36 Indifferent 
 TZP 500 3.26 0.67 0.56 0.84 Additive 
Graphite CIP 500 0.98 0.01 0.01 1.00 Additive 
 CHL 500 8.45 0.23 0.51 2.23 Indifferent 
 TZP 500 5.21 0.67 0.89 1.34 Indifferent 
Table 3. FIC analysis of CIP, CHL and TZP in combination with graphene, graphene 
oxide and graphite against E. coli. The fractional index points used were ≤ 0.5 synergy, ˃ 
0.5 ≤ 1 additivity, ˃ 1 ≤ 4 indifference and > 4 antagonism. (A) denotes carbon-based 
compound as shown, (B) represents antibiotics ciprofloxacin (CIP), chloramphenicol 
(CHL) and piperacillin/tazobactam (TZP). All MIC values are in mg/L. ∑FIC, sum of the 
fractional inhibitory concentrations. Values are representative of three independent 
biological repeats. 
Compound 
(A) 
Antibiotic 
(B) 
MIC 
(A) 
MIC 
(A+B) 
MIC 
(B) 
MIC 
(B+A) 
∑FIC Interaction 
Graphene CIP 250 0.98 0.01 0.01 1.00 Additive 
 CHL 250 1.63 0.08 0.10 1.26 Indifferent 
 TZP 250 0.98 0.17 0.17 1.00 Additive 
Graphene 
oxide 
CIP 333 0.98 0.01 0.01 1.00 Additive 
CHL 333 1.95 0.08 0.12 1.51 Indifferent 
 TZP 333 208 0.17 35.4 209 Antagonistic 
Graphite CIP 333 0.98 0.01 0.01 1.00 Additive 
 CHL 333 1.30 0.08 0.08 1.00 Additive 
 TZP 333 417 0.17 70.8 418 Antagonistic 
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However, for TZP the synergistic effects were more diverse across the three target bacteria. TZP 
used in combination with graphene resulted in additive interactions against E. coli (∑FIC = 1.00) 
(Table 3), indifferent activity against K. pneumoniae (∑FIC = 1.34) (Table 2) and antagonistic effects 
against E. faecium (∑FIC = 19.6) (Table 1). For TZP supplemented with graphene oxide, additive 
interactions were observed against K. pneumoniae (∑FIC = 0.84) (Table 2), whereas antagonistic 
effects occurred with this combination against E. faecium (Table 1) and E. coli (Table 3). When TZP 
was combined with graphite, indifferent activity was observed against E. faecium (∑FIC = 1.26) 
(Table 1) and K. pneumoniae (∑FIC = 1.34) (Table 2), whereas for E. coli, this combination was the 
most antagonistic (∑FIC = 418) (Table 3). 
Hydrochloric acid and ethanol solvent controls were used for MIC and FIC assays and these 
showed no effect on bacterial growth (data not shown). 
4. Discussion 
Three antibiotics were combined with carbon-based compounds to determine synergistic 
antimicrobial activity against three key priority pathogens. The antimicrobial activity of CIP was 
most potentiated by the addition of graphene, where additive activity was observed against E. 
faecium, K. pneumoniae and E. coli. The addition of adjuvants such as graphene, which enhance 
antibiotic action, permits lower levels of antibiotic usage overall [22]. For E. faecium, there was an 
observed one-fold less concentration of CIP required to inhibit bacterial growth in the presence of 
graphene. Given CIP targets bacterial nucleic acid synthesis and graphene has other reported 
mechanisms of antimicrobial action [4], it is thought that combinatorial therapy may help reduce the 
risk of antimicrobial resistance. Given graphene is thought to assist with membrane perturbation [3], 
it could be suggested that graphene works in combination with CIP by facilitating entry into the 
bacterial cell thereby exposing target sites for CIP. 
The combinations of CIP with graphene oxide or graphite also showed additive activity against 
both E. coli and K. pneumoniae but not the Gram-positive E. faecium. This may indicate that these 
carbon-based derivatives are more active against the outer membrane of Gram-negative pathogens. 
Graphene and graphene oxide enhanced the antimicrobial activity of TZP against E. coli and K. 
pneumoniae respectively, but were both antagonistic for TZP targeting of E. faecium. This is likely 
attributed to the mechanism of activity of TZP and the physiology of the Gram-positive bacteria. TZP 
localises to the bacterial cell wall where, through the action of the β-lactam piperacillin, will inhibit 
the action of penicillin binding proteins to prevent cell wall crosslinking and formation [18,20,23]. 
Graphene is thought to provide a film that encapsulates the bacterial cell [9], which may inhibit TZP 
from accessing the cell wall of E. faecium. Significant antimicrobial antagonism was observed when 
TZP was combined with graphene oxide and graphite against E. coli. Such phenomenon have been 
reported previously where vancomycin demonstrated highly antagonistic activity against E. coli 
when combined with other cell wall inhibitors such as TZP [24]. The mechanisms of antimicrobial 
action for graphene oxide and graphite are less clear [4] but these may either interact with TZP 
reducing effectiveness or prevent uptake of TZP into the E. coli cell. Further work is necessary to 
confirm such interactions. 
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5. Conclusion 
This is the first report where graphene and derivates potentiate the activity of specific antibiotics 
(CIP, TZP and CHL) against representative examples of both Gram-positive and Gram-negative 
bacteria. Other studies have demonstrated the antibacterial activity of graphene conjugates [13,14,15] 
and this study builds upon these advances by determining the potential for antibiotic-graphene 
synergistic activity. This may help inform future rational drug design, such as the addition of 
graphene to CIP for use against E. faecium, K. pneumoniae or E. coli. Using combination therapy 
where the antimicrobial agents have significantly different antibacterial mechanisms of activity may 
help reduce the risk of resistance evolution [11,22] and provide valuable solutions to treat the most 
serious of antibiotic resistant infections. 
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